再生医学在治疗终末期肝病中的临床应用
Clinical Application of Regenerative Medicine in the Treatment of End-Stage Liver Diseases
DOI: 10.12677/ACM.2022.1281048, PDF,   
作者: 刘 洪, 游海波:重庆市长寿区人民医院肝胆外科,重庆 ;王孟皓*:重庆医科大学附属第二医院肝胆外科,重庆
关键词: 肝脏再生再生医学终末期肝病临床应用Liver Regeneration Regenerative Medicine End-Stage Liver Disease Clinical Application
摘要: 感染、代谢紊乱、酗酒、恶性肿瘤等急慢性损伤均可导致终末期肝病(end-stage liver disease, ESLD)的发生。迄今为止,肝移植仍是治疗ESLD唯一被证实的有效手段。然而由于供体数量严重短缺,肝移植在临床中开展受到了极大限制,许多患者在等待器官过程中由于疾病进展而错失肝移植机会甚至死亡。因此,在临床中如何改善ESLD患者肝功能具有重要意义。再生医学作为组织工程和分子生物学转化研究的一个分支,旨在通过临床医学、材料科学及生命科学等前沿交叉领域对人体各种组织器官功能进行替代、修复甚至重建。肝脏作为哺乳动物体内唯一具有再生能力的内脏器官,在经历大部分切除(75%)后仍能基本恢复至原有功能从而满足机体代谢需求。正因其具有如此巨大的再生能力让肝脏在再生医学领域备受关注。肝脏再生医学主要包括自身组织再生、细胞疗法以及组织工程三个方面,本文将对近年来上述技术在治疗肝脏疾病中的临床应用进行综述。
Abstract: Acute and chronic damage such as infection, metabolic disorders, alcohol abuse, and malignant tu-mors can lead to the occurrence of end-stage liver disease (ESLD). Liver transplantation is still the only proven effective treatment for ESLD. However, due to the severe shortage of donor numbers, the clinical development of liver transplantation has been greatly limited. Many patients miss the opportunity of liver transplantation or even die due to disease progression while waiting for the donors. Therefore, how to improve liver function of ESLD patients is of great clinical significance. As a branch of tissue engineering and molecular biology transformation research, regenerative medi-cine aims to replace, repair and even reconstruct various tissues and organs in the human body through cutting-edge fields such as clinical medicine, materials science and life sciences. The liver, as the only regenerative visceral organ in the mammal, can still recover to its original function after subtotal hepatectomy (75%) to meet the metabolic needs of the body. Because of its huge regener-ative capacity, the liver has attracted much attention in the field of regenerative medicine. Liver regenerative medicine mainly includes three main aspects: self-regeneration, cell therapy and tis-sue engineering. This paper will review the clinical application of the above techniques in the treatment of liver diseases in recent years.
文章引用:刘洪, 游海波, 王孟皓. 再生医学在治疗终末期肝病中的临床应用[J]. 临床医学进展, 2022, 12(8): 7256-7263. https://doi.org/10.12677/ACM.2022.1281048

参考文献

[1] Diehl-Jones, W.L. and Askin, D.F. (2002) The Neonatal Liver, Part 1: Embryology, Anatomy, and Physiology. Neonatal Network: NN, 21, 5-12. [Google Scholar] [CrossRef] [PubMed]
[2] Higgins, G.M. and Anderson, R.M. (1931) Experimental Pathology of the Liver. I. Restoration of the Liver of the White Rat Following Partial Surgical Removal. Archives of Pathology & Laboratory Medicine, 12, 186-202.
[3] Liou, I.W. (2014) Management of End-Stage Liver Disease. The Medical Clinics of North America, 98, 119-152. [Google Scholar] [CrossRef] [PubMed]
[4] Olivo, R., Guarrera, J.V. and Pyrsopoulos, N.T. (2018) Liver Transplantation for Acute Liver Failure. Clinics in Liver Disease, 22, 409-417. [Google Scholar] [CrossRef] [PubMed]
[5] Soin, A.S., Chaudhary, R.J., Pahari, H., et al. (2019) A Worldwide Survey of Live Liver Donor Selection Policies at 24 Centers with a Combined Experience of 19009 Adult Living Donor Liver Transplants. Transplantation, 103, e39-e47. [Google Scholar] [CrossRef
[6] Miller, C.M., Quintini, C., Dhawan, A., et al. (2017) The In-ternational Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline. Transplantation, 101, 938-944. [Google Scholar] [CrossRef
[7] Nicolas, C.T., Hickey, R.D., Chen, H.S., et al. (2017) Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengi-neered Grafts. Stem Cells (Dayton, Ohio), 35, 42-50. [Google Scholar] [CrossRef] [PubMed]
[8] Rahbari, N.N., Garden, O.J., Padbury, R., et al. (2011) Posthepatectomy Liver Failure: A Definition and Grading by the International Study Group of Liver Surgery (ISGLS). Surgery, 149, 713-724. [Google Scholar] [CrossRef] [PubMed]
[9] Makuuchi, M., Thai, B.L., Takayasu, K., et al. (1990) Preoperative Portal Embolization to Increase Safety of Major Hepatectomy for Hilar Bile Duct Carcinoma: A Preliminary Report. Sur-gery, 107, 521-527.
[10] Adam, R., Laurent, A., Azoulay, D., et al. (2000) Two-Stage Hepatectomy: A Planned Strate-gy to Treat Irresectable Liver Tumors. Annals of Surgery, 232, 777-785. [Google Scholar] [CrossRef] [PubMed]
[11] Furrer, K., Tian, Y., Pfammatter, T., et al. (2008) Selec-tive Portal Vein Embolization and Ligation Trigger Different Regenerative Responses in the Rat Liver. Hepatology (Bal-timore, Md.), 47, 1615-1623. [Google Scholar] [CrossRef] [PubMed]
[12] Shindoh, J., Vauthey, J.N., Zimmitti, G., et al. (2013) Analysis of the Effi-cacy of Portal Vein Embolization for Patients with Extensive Liver Malignancy and Very Low Future Liver Remnant Volume, Including a Comparison with the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy Approach. Journal of the American College of Surgeons, 217, 126-133. [Google Scholar] [CrossRef] [PubMed]
[13] de Santibanes, E. and Clavien, P.A. (2012) Playing Play-Doh to Prevent Postoperative Liver Failure: The “ALPPS” Approach. Annals of Surgery, 255, 415-417. [Google Scholar] [CrossRef
[14] Schnitzbauer, A.A., Lang, S.A., Goessmann, H., et al. (2012) Right Portal Vein Ligation Combined with in Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings. Annals of Surgery, 255, 405-414. [Google Scholar] [CrossRef
[15] Olthof, P.B., Schnitzbauer, A.A. and Schadde, E. (2018) The HPB Controversy of the Decade: 2007-2017—Ten Years of ALPPS. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44, 1624-1627. [Google Scholar] [CrossRef] [PubMed]
[16] Chua, T.C., Liauw, W., Chu, F., et al. (2013) Summary Outcomes of Two-Stage Resection for Advanced Colorectal Liver Metastases. Journal of Surgical Oncology, 107, 211-216. [Google Scholar] [CrossRef] [PubMed]
[17] Schlegel, A., Lesurtel, M., Melloul, E., et al. (2014) ALPPS: From Human to Mice Highlighting Accelerated and Novel Mechanisms of Liver Regeneration. Annals of Surgery, 260, 839-846. [Google Scholar] [CrossRef
[18] Kwon, Y.J., Lee, K.G. and Choi, D. (2015) Clinical Implica-tions of Advances in Liver Regeneration. Clinical and Molecular Hepatology, 21, 7-13. [Google Scholar] [CrossRef] [PubMed]
[19] Schadde, E., Schnitzbauer, A.A., Tschuor, C., et al. (2015) System-atic Review and Meta-Analysis of Feasibility, Safety, and Efficacy of a Novel Procedure: Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. Annals of Surgical Oncology, 22, 3109-3120. [Google Scholar] [CrossRef] [PubMed]
[20] Tanaka, K., Matsuo, K., Murakami, T., et al. (2015) Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): Short-Term Outcome, Functional Changes in the Future Liver Remnant, and Tumor Growth Activity. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 41, 506-512. [Google Scholar] [CrossRef] [PubMed]
[21] Hernandez-Alejandro, R., Bertens, K.A., Pineda-Solis, K., et al. (2015) Can We Improve the Morbidity and Mortality Associated with the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure in the Management of Colorectal Liver Metastases? Surgery, 157, 194-201. [Google Scholar] [CrossRef] [PubMed]
[22] Hoekstra, L.T., van Lienden, K.P., Doets, A., et al. (2012) Tumor Progression after Preoperative Portal Vein Embolization. Annals of Surgery, 256, 812-817. [Google Scholar] [CrossRef
[23] Oldhafer, K.J., Donati, M., Jenner, R.M., et al. (2014) ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, But Early Tumor Recurrence. World Journal of Surgery, 38, 1504-1509. [Google Scholar] [CrossRef] [PubMed]
[24] Fukami, Y., Kurumiya, Y. and Kobayashi, S. (2014) Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): An Analysis of Tumor Activity. Updates in Surgery, 66, 223-225. [Google Scholar] [CrossRef] [PubMed]
[25] Hossein, A.M., Geramizadeh, B., Azarpira, N., et al. (2013) Hepatocyte Isolation from Unused/Rejected Livers for Transplantation: Initial Step toward Hepatocyte Transplantation, the First Experience from Iran. Hepatitis Monthly, 13, e10397. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, F., Zhou, L., Ma, X., et al. (2014) Monitoring of Intrasplenic Hepatocyte Transplantation for Acute-on-Chronic Liver Failure: A Prospective Five-Year Follow-Up Study. Transplantation Proceedings, 46, 192-198. [Google Scholar] [CrossRef] [PubMed]
[27] Jitraruch, S., Dhawan, A., Hughes, R.D., et al. (2014) Al-ginate Microencapsulated Hepatocytes Optimised for Transplantation in Acute Liver Failure. PLOS ONE, 9, e113609. [Google Scholar] [CrossRef] [PubMed]
[28] Dhawan, A., Puppi, J., Hughes, R.D., et al. (2010) Human Hepatocyte Transplantation: Current Experience and Future Challenges. Nature Reviews. Gastroenterology & Hepatology, 7, 288-298. [Google Scholar] [CrossRef] [PubMed]
[29] Lysy, P.A., Najimi, M., Stephenne, X., et al. (2008) Liver Cell Transplantation for Crigler-Najjar Syndrome Type I: Update and Perspectives. World Journal of Gastroenter-ology, 14, 3464-3470. [Google Scholar] [CrossRef] [PubMed]
[30] Fisher, R.A. and Strom, S.C. (2006) Human Hepatocyte Transplantation: Worldwide Results. Transplantation, 82, 441-449. [Google Scholar] [CrossRef] [PubMed]
[31] Nguyen, M.P., Jain, V., Iansante, V., et al. (2020) Clinical Application of Hepatocyte Transplantation: Current Status, Applicability, Limitations, and Future Outlook. Expert Review of Gastroenterology & Hepatology, 14, 185-196. [Google Scholar] [CrossRef] [PubMed]
[32] Sauer, V., Roy-Chowdhury, N., Guha, C., et al. (2014) In-duced Pluripotent Stem Cells as a Source of Hepatocytes. Current Pathobiology Reports, 2, 11-20. [Google Scholar] [CrossRef] [PubMed]
[33] Roy-Chowdhury, N., Wang, X., Guha, C., et al. (2017) Hepato-cyte-Like Cells Derived from Induced Pluripotent Stem Cells. Hepatology International, 11, 54-69. [Google Scholar] [CrossRef] [PubMed]
[34] Chen, Y., Li, Y., Wang, X., et al. (2015) Amelioration of Hyper-bilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes. Stem Cell Reports, 5, 22-30. [Google Scholar] [CrossRef] [PubMed]
[35] Huang, P., Zhang, L., Gao, Y., et al. (2014) Direct Reprogram-ming of Human Fibroblasts to Functional and Expandable Hepatocytes. Cell Stem Cell, 14, 370-384. [Google Scholar] [CrossRef] [PubMed]
[36] Ivanov, N.A., Tao, R., Chenoweth, J.G., et al. (2016) Strong Components of Epigenetic Memory in Cultured Human Fibroblasts Related to Site of Origin and Donor Age. PLoS Ge-netics, 12, e1005819. [Google Scholar] [CrossRef] [PubMed]
[37] Stock, P., Bruckner, S., Ebensing, S., et al. (2010) The Genera-tion of Hepatocytes from Mesenchymal Stem Cells and Engraftment into Murine Liver. Nature Protocols, 5, 617-627. [Google Scholar] [CrossRef] [PubMed]
[38] Faiella, W. and Atoui, R. (2016) Immunotolerant Properties of Mesen-chymal Stem Cells: Updated Review. Stem Cells International, 2016, Article ID: 1859567. [Google Scholar] [CrossRef] [PubMed]
[39] Sokal, E.M., Stephenne, X., Ottolenghi, C., et al. (2014) Liver En-graftment and Repopulation by in Vitro Expanded Adult Derived Human Liver Stem Cells in a Child with Ornithine Car-bamoyltransferase Deficiency. JIMD Reports, 13, 65-72. [Google Scholar] [CrossRef] [PubMed]
[40] Vishwakarma, S.K., Lakkireddy, C., Bardia, A., et al. (2018) Bioen-gineered Functional Humanized Livers: An Emerging Supportive Modality to Bridge the Gap of Organ Transplantation for Management of End-Stage Liver Diseases. World Journal of Hepatology, 10, 822-836. [Google Scholar] [CrossRef] [PubMed]
[41] Faulkner-Jones, A., Fyfe, C., Cornelissen, D.J., et al. (2015) Bi-oprinting of Human Pluripotent Stem Cells and Their Directed Differentiation into Hepatocyte-Like Cells for the Genera-tion of Mini-Livers in 3D. Biofabrication, 7, Article ID: 044102. [Google Scholar] [CrossRef] [PubMed]
[42] Lee, J.W., Choi, Y.J., Yong, W.J., et al. (2016) Development of a 3D Cell Printed Construct Considering Angiogenesis for Liver Tissue Engineering. Biofabrication, 8, Article ID: 015007. [Google Scholar] [CrossRef] [PubMed]
[43] Ma, X., Qu, X., Zhu, W., et al. (2016) Deterministi-cally Patterned Biomimetic Human iPSC-Derived Hepatic Model via Rapid 3D Bioprinting. Proceedings of the National Academy of Sciences of the United States of America, 113, 2206-2211. [Google Scholar] [CrossRef] [PubMed]
[44] Robbins, J.B., O’Neill, C.M., Gorgen, V., et al. (2013) Bioprinted Three-Dimensional (3D) Human Liver Constructs Provide a Model for Interrogating Liver Biology. American Society for Cell Biology, Rockville.
[45] Zhong, C., Xie, H.Y., Zhou, L., et al. (2016) Human Hepatocytes Loaded in 3D Bi-oprinting Generate Mini-Liver. Hepatobiliary & Pancreatic Diseases International, 15, 512-518. [Google Scholar] [CrossRef
[46] Lee, J.-S., Yoon, H., Yoon, D., et al. (2017) Development of Hepatic Blocks Using Human Adipose Tissue-Derived Stem Cells through Three-Dimensional Cell Printing Techniques. Journal of Materials Chemistry B, 5, 1098-1107. [Google Scholar] [CrossRef
[47] Koffler, J., Zhu, W., Qu, X., et al. (2019) Biomimetic 3D-Printed Scaf-folds for Spinal Cord Injury Repair. Nature Medicine, 25, 263-269. [Google Scholar] [CrossRef] [PubMed]